Truist analyst Lucas Servera raised the firm’s price target on RXO Inc. (RXO) to $20 from $18 and keeps a Buy rating on the shares after its Q4 results and guidance. The firm views RXO as increasingly attractive, with trough margins, strong pipeline visibility, and accelerating operating leverage setting up a sharper earnings recovery once volumes normalize, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXO:
- RXO Inc. price target lowered to $14 from $15 at JPMorgan
- RXO Inc. price target raised to $17 from $16 at BofA
- RXO Inc. price target raised to $17 from $15 at UBS
- Balanced Hold on RXO: Near-Term Earnings Pressure vs. Emerging Truckload Recovery Upside
- Balancing Near-Term Weakness and AI-Driven Upside: Why RXO Merits a Buy Rating